Paragon Therapeutics reports 3.39% stake in Damora

Paragon Therapeutics, Inc. amended its Schedule 13G to report beneficial ownership of 2,045,473 shares of Damora Therapeutics common stock.

Rhea-AI Filing Summary

Paragon Therapeutics, Inc. amended its Schedule 13G to report beneficial ownership of 2,045,473 shares of Damora Therapeutics common stock. The filing states this position represents 3.39% of the class, calculated using 60,303,212 shares outstanding as of March 17, 2026 reported in Damora's Annual Report on Form 10-K. Paragon lists sole voting and sole dispositive power over the shares and is organized in Delaware. The amendment is signed by Keri Lantz, Chief Financial Officer on April 23, 2026.

Insights

Corporate Governance Analyst

Paragon discloses a passive stake just above a 3% threshold.

Paragon Therapeutics reports ownership of 2,045,473 shares, which the filing labels as 3.39% of Damora's outstanding common stock using the issuer's stated share count as of March 17, 2026. The filing lists sole voting and dispositive power, indicating direct control over voting decisions for that block.

Because Schedule 13G/A typically reflects passive or qualifying institutional ownership, this disclosure signals a measurable minority stake but not a controlling position. Subsequent filings would clarify any change in intent or voting plans.

Key Figures

Shares beneficially owned: 2,045,473 shares Percent of class: 3.39% Shares outstanding used: 60,303,212 shares

3 metrics

Shares beneficially owned 2,045,473 shares Paragon Therapeutics reported amount

Percent of class 3.39% Calculated using shares outstanding as of March 17, 2026

Shares outstanding used 60,303,212 shares As of March 17, 2026, per Damora's Form 10-K

Key Terms

Schedule 13G/A, beneficial ownership, sole dispositive power

3 terms

Schedule 13G/A regulatory

"Amendment No. 1 to Schedule 13G (ownership disclosure)"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficial ownership financial

"Amount beneficially owned: See the response to Item 9"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

sole dispositive power financial

"Sole Dispositive Power 2,045,473.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Paragon Therapeutics report in Damora Therapeutics (DMRA)?

Paragon Therapeutics reports beneficial ownership of 2,045,473 shares, equal to 3.39% of Damora's common stock, based on a 60,303,212 share outstanding count as of March 17, 2026 reported in the issuer's Form 10-K.

Who has voting and dispositive power over the DMRA shares reported by Paragon?

The filing states Paragon Therapeutics holds sole voting power and sole dispositive power over the 2,045,473 shares, indicating Paragon controls both how the shares are voted and when they may be sold.

What reporting form did Paragon use to disclose its DMRA ownership?

Paragon filed an Amendment No. 1 to Schedule 13G (a 13G/A), which is used for reporting certain passive or qualifying institutional ownership changes under SEC rules.

What share count did the filing use to compute the 3.39% ownership in DMRA?

The percentage is based on 60,303,212 shares outstanding as of March 17, 2026, as cited from Damora's Annual Report on Form 10-K filed March 19, 2026, and referenced in the Schedule 13G/A amendment.

Who signed the Schedule 13G/A amendment for Paragon Therapeutics?

Keri Lantz, Chief Financial Officer, signed the amendment on April 23, 2026, certifying the ownership and power disclosures shown in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 09:19 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Damora Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

36322Q206

(CUSIP Number)

02/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 36322Q206

1

Names of Reporting Persons

Paragon Therapeutics, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,045,473.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,045,473.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,045,473.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.39 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Row 11 is based on 60,303,212 shares of Common Stock outstanding as of March 17, 2026 as reported in the Issuer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission on March 19, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Damora Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453
Item 2.
(a)	Name of person filing: Paragon Therapeutics, Inc.
(b)	Address or principal business office or, if none, residence: 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453
(c)	Citizenship: Delaware
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 36322Q206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response to Item 9 on the attached cover page.
(b)	Percent of class: See the response to Item 11 on the attached cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response to Item 5 on the attached cover page.
	(ii) Shared power to vote or to direct the vote: See the response to Item 6 on the attached cover page.
	(iii) Sole power to dispose or to direct the disposition of: See the response to Item 7 on the attached cover page.
	(iv) Shared power to dispose or to direct the disposition of: See the response to Item 8 on the attached cover page.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paragon Therapeutics, Inc.

Signature:	/s/ Keri Lantz
Name/Title:	Keri Lantz, Chief Financial Officer
Date:	04/23/2026